Axsome Common Stock Total Equity vs Short Term Debt Analysis
AXSM Stock | USD 97.74 1.08 1.09% |
Axsome Therapeutics financial indicator trend analysis is way more than just evaluating Axsome Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Axsome Therapeutics is a good investment. Please check the relationship between Axsome Therapeutics Common Stock Total Equity and its Short Term Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.
Common Stock Total Equity vs Short Term Debt
Common Stock Total Equity vs Short Term Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Axsome Therapeutics Common Stock Total Equity account and Short Term Debt. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Axsome Therapeutics' Common Stock Total Equity and Short Term Debt is -0.36. Overlapping area represents the amount of variation of Common Stock Total Equity that can explain the historical movement of Short Term Debt in the same time period over historical financial statements of Axsome Therapeutics, assuming nothing else is changed. The correlation between historical values of Axsome Therapeutics' Common Stock Total Equity and Short Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Total Equity of Axsome Therapeutics are associated (or correlated) with its Short Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Debt has no effect on the direction of Common Stock Total Equity i.e., Axsome Therapeutics' Common Stock Total Equity and Short Term Debt go up and down completely randomly.
Correlation Coefficient | -0.36 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Common Stock Total Equity
The total value of common stock equity held by shareholders, representing their ownership interest in the company.Short Term Debt
Most indicators from Axsome Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Axsome Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.At this time, Axsome Therapeutics' Selling General Administrative is very stable compared to the past year. As of the 12th of December 2024, Tax Provision is likely to grow to about 1 M, while Sales General And Administrative To Revenue is likely to drop 0.78.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 5.7M | 7.3M | 6.5M | 6.8M | Depreciation And Amortization | 1.2M | 5.6M | 6.8M | 7.2M |
Axsome Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Axsome Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Axsome Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 220.5M | 186.1M | (338.4M) | 331.5M | 588.2M | 617.6M | |
Short Long Term Debt Total | 19.9M | 50.1M | 49.7M | 94.7M | 186.4M | 195.7M | |
Other Current Liab | 683.2K | 8.7M | 9.3M | 57.5M | 95.6M | 100.4M | |
Total Current Liabilities | 24.5M | 23.4M | 23.1M | 96.6M | 138.9M | 145.8M | |
Total Stockholder Equity | (175.9M) | (278.8M) | (409.2M) | 109.6M | 191.0M | 200.5M | |
Net Debt | (200.0M) | (133.8M) | (36.8M) | (106.2M) | (199.8M) | (189.8M) | |
Retained Earnings | (175.9M) | (278.8M) | (409.2M) | (596.3M) | (835.6M) | (793.8M) | |
Accounts Payable | 10.9M | 13.5M | 13.1M | 38.6M | 40.7M | 42.7M | |
Cash | 220.0M | 183.9M | 86.5M | 200.8M | 386.2M | 405.5M | |
Cash And Short Term Investments | 220.0M | 183.9M | 86.5M | 200.8M | 386.2M | 405.5M | |
Common Stock Total Equity | 3.0K | 3.7K | 3.7K | 3.8K | 4.3K | 2.7K | |
Common Stock Shares Outstanding | 34.0M | 37.2M | 37.6M | 40.7M | 45.4M | 30.1M | |
Liabilities And Stockholders Equity | (134.1M) | (206.5M) | (338.4M) | 331.5M | 588.2M | 617.6M | |
Other Current Assets | 413.1K | 148.4K | 45.3K | 5.6M | 8.1M | 8.5M | |
Other Stockholder Equity | (3.7K) | 392.6M | 424.8M | 705.9M | 1.0B | 1.1B | |
Total Liab | 41.8M | 72.3M | 70.8M | 221.9M | 397.3M | 417.1M | |
Total Current Assets | 220.4M | 184.0M | 86.5M | 245.6M | 504.3M | 529.5M | |
Short Term Debt | 2.6M | 1.2M | 620.7K | 425K | 2.5M | 1.4M | |
Common Stock | 3.7K | 3.7K | 3.8K | 4.4K | 5K | 3.2K | |
Net Tangible Assets | 178.7M | 113.8M | 15.6M | 39.6M | 45.5M | 52.6M | |
Non Current Assets Total | 170.5K | 2.1M | 1.3M | 85.8M | 84.0M | 88.2M | |
Non Currrent Assets Other | 139.9K | 317.4K | 322.9K | 14.7M | 11.0M | 11.6M | |
Other Assets | 139.9K | 2.1M | (426.1M) | 14.7M | 13.2M | 13.9M | |
Long Term Debt | 17.3M | 48.3M | 49.1M | 94.3M | 178.1M | 187.0M | |
Non Current Liabilities Total | 17.3M | 48.9M | 49.1M | 125.4M | 258.4M | 271.3M | |
Property Plant And Equipment Net | 30.6K | 1.8M | 944.0K | 1.1M | 7.6M | 8.0M | |
Property Plant And Equipment Gross | 30.6K | 1.8M | 944.0K | 1.1M | 7.6M | 8.0M | |
Property Plant Equipment | 30.6K | 52.6K | 283.8K | 1.1M | 1.3M | 1.4M | |
Retained Earnings Total Equity | (107.6M) | (175.9M) | (278.8M) | (409.2M) | (368.3M) | (349.9M) | |
Long Term Debt Total | 3.6M | 17.3M | 48.3M | 49.1M | 56.5M | 59.3M | |
Capital Surpluse | 108.5M | 354.6M | 392.6M | 424.8M | 488.5M | 264.6M | |
Net Invested Capital | 198.7M | 162.1M | 64.7M | 203.8M | 369.0M | 387.5M | |
Net Working Capital | 195.9M | 160.6M | 63.5M | 149.1M | 365.4M | 383.7M | |
Capital Stock | 3.7K | 3.7K | 3.8K | 4.4K | 5K | 4.3K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.58) | Revenue Per Share 7.108 | Quarterly Revenue Growth 0.813 | Return On Assets (0.26) | Return On Equity (1.72) |
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.